{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-005425","form_type":"8-K","ticker":"BBOT","cik":"0001869105","company_name":"BridgeBio Oncology Therapeutics, Inc.","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.620363+00:00","generated_at":"2026-05-16T11:25:05.110496+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BBOT reports 65% ORR for BBO-8520, first panKRAS response in PDAC, no hyperglycemia with BBO-10203","bullets":["BBO-8520 monotherapy: 65% ORR (11/17), 66% 6-month PFS, including one complete response; all 5 STK11/KEAP1 co-mutant patients achieved PR.","BBO-8520 + pembrolizumab: all 8 evaluable patients had tumor reduction; 3/3 front-line and 2/5 prior KRAS G12C inhibitor patients achieved PR.","BBO-11818 panKRAS inhibitor: first monotherapy PR in pancreatic ductal adenocarcinoma (44% tumor reduction); dose-proportional exposure covering G12D/G12V at 600 mg BID.","BBO-10203 RAS:PI3Kα breaker: no hyperglycemia of any grade, no baseline HbA1c/glucose restrictions; 500 mg QD selected for expansion; combination studies initiated.","Combination studies of BBO-8520, BBO-11818, and BBO-10203 with each other and with standard-of-care expected to open in H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-005425","json":"https://secwatch.observer/filing/0001193125-26-005425.json","markdown":"https://secwatch.observer/filing/0001193125-26-005425.md","text":"https://secwatch.observer/filing/0001193125-26-005425.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526005425/0001193125-26-005425-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526005425/d941846d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:25:05.110496+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}